Biogeneric Drugs Market Report – Research, Industry Analysis Reports and Market Demands

Global Biogeneric Drugs Market Insights, Forecast to 2025

Request for Sample of this report

Buy now

Table of Content

1 Study Coverage

1.1 Biogeneric Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
- 1.4.1 Global Biogeneric Drugs Market Size Growth Rate by Product
- 1.4.2 Insulins
- 1.4.3 Growth Hormones
- 1.4.4 Monoclonal Antibodies
- 1.4.5 Others
1.5 Market by End User
- 1.5.1 Global Biogeneric Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinics
- 1.5.4 Research Centers
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary

2.1 Global Biogeneric Drugs Market Size
- 2.1.1 Global Biogeneric Drugs Revenue 2014-2025
- 2.1.2 Global Biogeneric Drugs Sales 2014-2025
2.2 Biogeneric Drugs Growth Rate by Regions
- 2.2.1 Global Biogeneric Drugs Sales by Regions
- 2.2.2 Global Biogeneric Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Biogeneric Drugs Sales by Manufacturers
- 3.1.1 Biogeneric Drugs Sales by Manufacturers
- 3.1.2 Biogeneric Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Biogeneric Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Biogeneric Drugs Revenue by Manufacturers
- 3.2.1 Biogeneric Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Biogeneric Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Biogeneric Drugs Price by Manufacturers
3.4 Biogeneric Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Biogeneric Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Biogeneric Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Biogeneric Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

4.1 Global Biogeneric Drugs Sales by Product
4.2 Global Biogeneric Drugs Revenue by Product
4.3 Biogeneric Drugs Price by Product

5 Breakdown Data by End User

5.1 Overview
5.2 Global Biogeneric Drugs Breakdown Data by End User

6 North America

6.1 North America Biogeneric Drugs by Countries
- 6.1.1 North America Biogeneric Drugs Sales by Countries
- 6.1.2 North America Biogeneric Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
6.2 North America Biogeneric Drugs by Product
6.3 North America Biogeneric Drugs by End User

7 Europe

7.1 Europe Biogeneric Drugs by Countries
- 7.1.1 Europe Biogeneric Drugs Sales by Countries
- 7.1.2 Europe Biogeneric Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
7.2 Europe Biogeneric Drugs by Product
7.3 Europe Biogeneric Drugs by End User

8 Asia Pacific

8.1 Asia Pacific Biogeneric Drugs by Countries
- 8.1.1 Asia Pacific Biogeneric Drugs Sales by Countries
- 8.1.2 Asia Pacific Biogeneric Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
8.2 Asia Pacific Biogeneric Drugs by Product
8.3 Asia Pacific Biogeneric Drugs by End User

9 Central & South America

9.1 Central & South America Biogeneric Drugs by Countries
- 9.1.1 Central & South America Biogeneric Drugs Sales by Countries
- 9.1.2 Central & South America Biogeneric Drugs Revenue by Countries
- 9.1.3 Brazil
9.2 Central & South America Biogeneric Drugs by Product
9.3 Central & South America Biogeneric Drugs by End User

10 Middle East and Africa

10.1 Middle East and Africa Biogeneric Drugs by Countries
- 10.1.1 Middle East and Africa Biogeneric Drugs Sales by Countries
- 10.1.2 Middle East and Africa Biogeneric Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
10.2 Middle East and Africa Biogeneric Drugs by Product
10.3 Middle East and Africa Biogeneric Drugs by End User

11 Company Profiles

12 Future Forecast

12.1 Biogeneric Drugs Market Forecast by Regions
- 12.1.1 Global Biogeneric Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Biogeneric Drugs Revenue Forecast by Regions 2019-2025
12.2 Biogeneric Drugs Market Forecast by Product
- 12.2.1 Global Biogeneric Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Biogeneric Drugs Revenue Forecast by Product 2019-2025
12.3 Biogeneric Drugs Market Forecast by End User
12.4 North America Biogeneric Drugs Forecast
12.5 Europe Biogeneric Drugs Forecast
12.6 Asia Pacific Biogeneric Drugs Forecast
12.7 Central & South America Biogeneric Drugs Forecast
12.8 Middle East and Africa Biogeneric Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

14.1 Value Chain Analysis
14.2 Biogeneric Drugs Customers
14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
16.2 Author Details

Description

Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illness because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.
Biogeneric drugs market is expected to increase in forecast period due to increased treatment options, value added services to care patient and healthcare community. Due to drugs introduces competition, increasing affordability of biologics which delivers saving for healthcare systems are the same factors which increase biogeneric drugs market. Introduction of affordable, high-quality biogenerics drugs improves access to life changing medicine for patients worldwide. Opportunities for generic drug products is huge but there are regulations that must be adhered to when strategizing the best ways to maximize a company’s return. Government regulation may be adhere the growth of drug development investment or planning an entry into a market with a new biogeneric products.
The global Biogeneric Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Biogeneric Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Biogeneric Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biogeneric Drugs in these regions.
This research report categorizes the global Biogeneric Drugs market by top players/brands, region, type and end user. This report also studies the global Biogeneric Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance life sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG life Science
Dong-A Pharmaceutical

Market size by Product
Insulins
Growth Hormones
Monoclonal Antibodies
Others
Market size by End User
Hospital
Clinics
Research Centers

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Biogeneric Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Biogeneric Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Biogeneric Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Biogeneric Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Biogeneric Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biogeneric Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.